Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH study

Blood Pressure

Volumn 21, Issue 2, 2012, Pages 82-87

  Kjeldsen, Sverre E ^a,b   Jamerson, Kenneth A ^a   Bakris, George L ^c   Pitt, Bertram ^a   Dahlöf, Björn ^d   Velazquez, Eric J ^e   Hua, Tsushung A ^f   Kelly, Roxzana Y ^f   Zappe, Dion ^f   Hester, Allen ^f   Tuomilehto, Jaakko ^g   Östergren, Jan ^h   Ibsen, Hans ⁱ   Weber, Michael ^j  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF CHICAGO   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF HELSINKI   (Finland)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^j Downstate Health Sciences University   (United States)

more..

Author keywords

clinical trial; combination therapy; hypertension; predictor variables

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROCHLOROTHIAZIDE; ORAL ANTIDIABETIC AGENT; THIAZIDE DIURETIC AGENT;

ARTICLE; BODY MASS; CAUCASIAN; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ELECTROCARDIOGRAM; ETHNICITY; GENDER; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEINURIA; SMOKING; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; UNSTABLE ANGINA PECTORIS;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOGISTIC MODELS; MALE; SYSTOLE;

EID: 84859055260     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2011.598699     Document Type: Article

References (17)

1. Jamerson K, Weber MA, Bakris GL, Dahlö f B, Pitt B, Shi V, et al. Benazepril plus amlodipine orhydrochlorothiazide for hypertension in high-risk patients. New Engl J Med. 2008;359:2417-28.
2. Jamerson K, Bakris GL, Dahlö f B, Pitt B, Velazquez E, Gupte J, et al. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Press. 2007;16:80-86. (Pubitemid 47050368)
3. Kjeldsen SE, Jamerson K, Bakris G, Pitt B, Dahlö f B, Velazquez EJ, et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. Blood Press. 2008;17:7-17. (Pubitemid 351890487)
4. Jamerson KA, Bakris GL, Wun CC, Dahlö f B, Lefkowitz M, Manfreda S, et al. Rationale and design of the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) Trial. Am J Hypertens. 2004;17:793-801.
5. Weber MA, Bakris GL, Dahlö f B, Pitt B, Velazquez E, Gupte J, et al. Hypertensive patients at high cardiovascular risk: Baseline findings in the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial. Blood Press. 2007;16:13-19. (Pubitemid 46672249)
6. Wolf HK, Tuomilehto J, Kuulasmaa K, Domarkiene S, Cepaitis Z, Molarius A, et al. for WHO MONICA. Blood pressure levels in the 41 populations of the WHO MONICA project. J Human Hypertens 1997;12:733-742. (Pubitemid 27503986)
7. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2362-2369.
8. Hansson L, Zanchetti A, Carruthers SG, Dahlö f B, Elmfeldt D, Julius S, et al. for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762. (Pubitemid 28269185)
9. Kjeldsen SE, Dahlö f B, Devereux RB, Julius S, de Faire U, Fyhrquist F, et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy. Am J Hypertens. 2000;13:899-906.
10. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, et al. VALUE Trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16:544-8. (Pubitemid 36829703)
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
12. Julius S, Kjeldsen S, Weber M, Brunner HR, Ekman S, Hansson L, et al. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet. 2004;363:2022-2031.
13. Poulter NR, Wedel H, Dahlö f B, Sever PS, Beevers DG, Caulfield M, et al. for the ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907-913.
14. Campo C, Segura J, Ruilope LM. Factors influencing the systolic blood pressure response to drug therapy. J Clin Hypertens. 2002;4:35-40. (Pubitemid 34163044)
15. Dahl öf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial. Lancet. 2005;366:895-906.
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC7 Report. JAMA. 2003;289:2560-2572. (Pubitemid 37430158)
17. 2007 ESH-ESC Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007;16:135-232.